A clinical trial of 699 children and adolescents (aged 10–17 years) with recent-onset type 2 diabetes has found that combined treatment with metformin and rosiglitazone is superior to treatment with metformin alone or metformin plus a lifestyle-intervention program in maintaining glycemic control. No adverse renal effects, including microalbuminuria, hypertension and renal impairment, were reported during the trial.
ORIGINAL RESEARCH PAPER
Original article TODAY Study Group. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N. Engl. J. Med. doi: 10.1056/NEJMoa1109333
Rights and permissions
About this article
Cite this article
Treatments for type 2 diabetes do not affect renal function. Nat Rev Nephrol 8, 372 (2012). https://doi.org/10.1038/nrneph.2012.98
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2012.98